Go Pro
NASDAQ:DRTS

Alpha Tau Medical (DRTS) Stock Price, News & Analysis

Alpha Tau Medical logo
$13.14 0.00 (0.00%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$13.04 -0.11 (-0.80%)
As of 08/7/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Alpha Tau Medical Stock (NASDAQ:DRTS)

Advanced

Key Stats

Today's Range
$13.10
$13.50
50-Day Range
$8.93
$13.57
52-Week Range
$3.00
$14.11
Volume
292,199 shs
Average Volume
576,034 shs
Market Capitalization
$1.19 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.60
Consensus Rating
Moderate Buy

Company Overview

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors. Alpha DaRT implants release alpha-emitting atoms that diffuse a few millimeters into the tumor, providing localized radiation doses that have shown promising preclinical and early clinical anti‐tumor activity. Alpha Tau Medical has secured Breakthrough Device designation from the U.S. Food and Drug Administration for certain cancer types and is advancing its pipeline through multi‐center trials in Europe and Israel.

Alpha Tau Medical collaborates with major oncology centers and academic institutions to conduct its clinical programs and to explore combination approaches with immunotherapies and other treatment modalities. The company has expanded its operational footprint beyond Israel, engaging regulatory and commercial partners in Europe while preparing for potential U.S. market entry. Through its focused R&D efforts and strategic alliances, Alpha Tau Medical seeks to establish alpha‐particle brachytherapy as a new standard of care for patients with challenging solid tumors.

AI Generated. May Contain Errors.

Alpha Tau Medical Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
32nd Percentile Overall Score

DRTS MarketRank™: 

Alpha Tau Medical scored higher than 32% of companies evaluated by MarketBeat, and ranked 736th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Alpha Tau Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 5 buy ratings, 2 hold ratings, and 1 sell rating.

  • Upside/Downside

    The consensus price target for Alpha Tau Medical is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Alpha Tau Medical has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Alpha Tau Medical's stock forecast and price target.
  • Earnings Growth

    Earnings for Alpha Tau Medical are expected to grow in the coming year, from ($0.67) to ($0.51) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Alpha Tau Medical is -19.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Alpha Tau Medical is -19.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Alpha Tau Medical has a P/B Ratio of 14.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Alpha Tau Medical's valuation and earnings.
  • Percentage of Shares Shorted

    5.45% of the float of Alpha Tau Medical has been sold short.
  • Short Interest Ratio / Days to Cover

    Alpha Tau Medical has a short interest ratio ("days to cover") of 3.66, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Alpha Tau Medical has recently increased by 35.07%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Alpha Tau Medical does not currently pay a dividend.

  • Dividend Growth

    Alpha Tau Medical does not have a long track record of dividend growth.

  • News Sentiment

    Alpha Tau Medical has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Alpha Tau Medical this week, compared to 4 articles on an average week.
  • MarketBeat Follows

    3 people have added Alpha Tau Medical to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Alpha Tau Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,270,923.00 in company stock.

  • Percentage Held by Insiders

    39.50% of the stock of Alpha Tau Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    2.65% of the stock of Alpha Tau Medical is held by institutions.

  • Read more about Alpha Tau Medical's insider trading history.
Receive DRTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alpha Tau Medical and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DRTS Stock News Headlines

Real reason Trump banning Chinese models
President Trump's administration is drafting a ban on Chinese-made components used inside American AI data centers - not chips, but a small, overlooked part that moves data through every facility. The move stems from a new economic doctrine crafted by a controversial Silicon Valley CEO, one already reshaping which companies are considered safe investments. Analysts Porter Stansberry and Luke Lango break down the full story and the shifts investors should watch.tc pixel
See More Headlines

DRTS Stock Analysis - Frequently Asked Questions

Alpha Tau Medical's stock was trading at $4.95 at the beginning of the year. Since then, DRTS shares have increased by 165.5% and is now trading at $13.14.

Alpha Tau Medical Ltd. (NASDAQ:DRTS) posted its earnings results on Monday, May, 18th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.13.

Top institutional investors of Alpha Tau Medical include Everhart Financial Group Inc. (0.01%).
View institutional ownership trends
.

Shares of DRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alpha Tau Medical investors own include Datadog (DDOG), Advanced Micro Devices (AMD), Broadcom (AVGO), Meta Platforms (META), PayPal (PYPL), Sunrun (RUN) and ZIM Integrated Shipping Services (ZIM).

Company Calendar

Last Earnings
5/18/2026
Today
8/09/2026
Next Earnings (Estimated)
8/10/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:DRTS
CIK
1871321
Fax
N/A
Employees
80
Year Founded
2016

Price Target and Rating

High Price Target
$17.00
Low Price Target
$8.00
Potential Upside/Downside
-4.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.67)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$42.63 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-73.23%
Return on Assets
-52.90%

Debt

Debt-to-Equity Ratio
0.09
Current Ratio
7.79
Quick Ratio
7.79

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.88 per share
Price / Book
14.93

Miscellaneous

Outstanding Shares
90,330,000
Free Float
54,647,000
Market Cap
$1.19 billion
Optionable
No Data
Beta
1.17

Social Links

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (NASDAQ:DRTS) was last updated on 8/10/2026 by MarketBeat.com Staff.
From Our Partners